

SNIPR BIOME Strengthens Lead in CRISPR-based Medicines to Treat Microbiomes

- SNIPR BIOME granted 4 more patents covering the application of CRISPR/Cas technology
- The approach enables the development of highly selective antibacterial medicines which will overcome antibiotic resistance
- The patents include methods that modulate the efficacy of PD-1/PD-L1 immune checkpoint inhibitors and other immunotherapies.

Copenhagen, January 7th, 2020: SNIPR BIOME ApS, a pioneering CRISPR and microbiome biotechnology company, today announced that the US Patent & Trademark Office has granted the company 4 more patents covering the application of CRISPR/Cas technology to treat infections and to cut bacterial genomes multiple times.

The approach enables the development of new highly selective antibacterial medicines which overcome antibiotic resistance seen increasingly with conventional drugs. The company is applying its CRISPR technology platform to address unmet medical needs in infectious diseases, cancer and inflammatory disorders. It is using the \$50m series A equity raised in 2019 to further develop the technology and advance highly novel products into the clinic.

The patents reinforce SNIPR BIOME's growing patent estate for the application of Cas3, Cas9 and other Cas systems to medicine.

Patents, US10,524,477 and US10,463,049 entitled "*Altering microbial populations and modifying microbiota*", protect the multiplex cutting innovation, whilst patent US10,506,812 provides exclusive protection for the use of Cas3 to treat any infection. SNIPR BIOME has the earliest position in the field for such use of Cas3 systems.

A further patent, US10,363,308, protects approaches that alter patients' microbiomes to enhance immunotherapy efficacy and influence immuno-oncology outcomes. The granted patents include methods that modulate the efficacy of PD-1/PD-L1 immune checkpoint inhibitors and other immunotherapies.

Dr. Christian Grøndahl, Co-founder & CEO commented:

"I am delighted that we have been granted 4 more US patents taking our total to 8 patents. This places SNIPR BIOME at the forefront of the CRISPR and microbiome revolution. Using our novel CRISPR platform, we are developing therapies to selectively kill bacteria and re-program microbiomes. We look forward to advancing our innovative, life-changing medicines into the clinic and building collaborative partnerships that have the potential to transform patients' lives."

For more information, please contact:

CEO, Christian Grøndahl / E-mail: cg@sniprbiome.com / Mobile: +45 20202747

About SNIPR BIOME

SNIPR BIOME is a leading CRISPR and microbiome biotech company incorporated in Copenhagen, Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs deploying its proprietary and patent-protected CRISPR/Cas platform. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient's microbial community intact. In March 2019, SNIPR BIOME closed a \$50 million Series A financing by Lundbeckfonden Emerge (Copenhagen), Life Sciences Partners (Amsterdam), North-East Family Office (Copenhagen) and Wellington Partners (Munich).

For more details, please visit: www.sniprbiome.com